private digital health companies weight loss glp-1 The next phase of the obesity drug race 9 Companies Developing Next-Generation GLP-1

1,340 The rise in cAMP further activates PKA, which can inhibit the NF-B signaling pathway, reducing the production of inflammatory factors such as iNOS and other inflammation-related proteins

Special populations and timing considerations Certain groups face unique timing challenges that deserve specific attention

Follow-up cadence : monthly during titration, quarterly during maintenance

These products are not FDA-approved drugs

Health and regulatory authorities are currently looking into implementing unit serialization (Policy paper on traceability of medical products, WHO, 2021) to improve traceability from production through to patients